PhRMA Pushing For Policies To Facilitate Outcomes-Based Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry group is promoting policy changes such as allowing broader communications with payers and a safe harbor for patient adherence programs that may help manufacturers and payers negotiate outcomes-based contracts for biopharma products.
You may also be interested in...
HHS Raises Profile In Drug Costs Discussion
On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.